4.3 Article

Real-time cell viability assays using a new anthracycline derivative DRAQ7®

Journal

CYTOMETRY PART A
Volume 83A, Issue 2, Pages 227-234

Publisher

WILEY-BLACKWELL
DOI: 10.1002/cyto.a.22228

Keywords

DRAQ7; real-time assays; cell viability; drug; cytotoxicity; DNA damage response; cell cycle; microfluidic; cytometry

Funding

  1. NCN [UMO-2011/01/B/NZ3/00609]
  2. EU [POIG.02.01.00-12-064/08]
  3. EPSRC Basic technology [EP/F040954/1]
  4. NCI CA [RO1 28 704]
  5. Faculty Research Development Fund, University of Auckland
  6. University of Auckland
  7. Ministry of Science and Innovation (MSI), New Zealand
  8. On-Chip Biotechnologies Co., Ltd.
  9. EPSRC [EP/F040954/1] Funding Source: UKRI
  10. Engineering and Physical Sciences Research Council [EP/F040954/1] Funding Source: researchfish

Ask authors/readers for more resources

The exclusion of charged fluorescent dyes by intact cells has become a well-established assay for determining viability of cells. In search for a noninvasive fluorescent probe capable of long-term monitoring of cell death in real-time, we evaluated a new anthracycline derivative DRAQ7. The novel probe does not penetrate the plasma membrane of living cells but when the membrane integrity is compromised, it enters and binds readily to nuclear DNA to report cell death. It proved to be nontoxic to a panel of cancer cell lines grown continuously for up to 72 h and did not induce any detectable DNA damage signaling when analyzed using laser scanning microscopy and flow cytometry. The DRAQ7 provided a sensitive, real-time readout of cell death induced by a variety of stressors such as hypoxia, starvation, and drug-induced cytotoxicity. The overall responses to anticancer agents and resulting pharmacological dose-response profiles were not affected by the growth of tumor cells in the presence DRAQ7. Moreover, we for the first time introduced a near real-time microflow cytometric assay based on combination of DRAQ7 and mitochondrial inner membrane potential (??m) sensitive probe TMRM. We provide evidence that this low-dosage, real-time labeling procedure provides multiparameter and kinetic fingerprint of anticancer drug action. (C) 2012 International Society for Advancement of Cytometry

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available